Literature DB >> 28172488

Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.

Vincent Lo Re1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28172488      PMCID： PMC5850615          DOI： 10.1093/cid/ciw814

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   20.999


× No keyword cloud information.
  30 in total

1.  High hepatic and extrahepatic mortality and low treatment uptake in HCV-coinfected persons in the Swiss HIV cohort study between 2001 and 2013.

Authors:  Helen Kovari; Bruno Ledergerber; Matthias Cavassini; Juan Ambrosioni; Andrea Bregenzer; Marcel Stöckle; Enos Bernasconi; Roger Kouyos; Rainer Weber; Andri Rauch
Journal:  J Hepatol       Date:  2015-05-01       Impact factor: 25.083

2.  Interferon-based therapy reduces risk of stroke in chronic hepatitis C patients: a population-based cohort study in Taiwan.

Authors:  C-S Hsu; J-H Kao; Y-C Chao; H H Lin; Y-C Fan; C-J Huang; P-S Tsai
Journal:  Aliment Pharmacol Ther       Date:  2013-06-26       Impact factor: 8.171

3.  Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients coinfected with HIV and Hepatitis C virus.

Authors:  Juan Berenguer; Elena Rodríguez; Pilar Miralles; Miguel A Von Wichmann; José López-Aldeguer; Josep Mallolas; María J Galindo; Eva Van Den Eynde; María J Téllez; Carmen Quereda; Antoni Jou; José Sanz; Carlos Barros; Ignacio Santos; Federico Pulido; Josep M Guardiola; Enrique Ortega; Rafael Rubio; Juan J Jusdado; María L Montes; Gabriel Gaspar; Herminia Esteban; José M Bellón; Juan González-García
Journal:  Clin Infect Dis       Date:  2012-05-18       Impact factor: 9.079

4.  The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C.

Authors:  Matthew S Freiberg; Chung-Chou H Chang; Melissa Skanderson; Kathleen McGinnis; Lewis H Kuller; Kevin L Kraemer; David Rimland; Matthew B Goetz; Adeel A Butt; Maria C Rodriguez Barradas; Cynthia Gibert; David Leaf; Sheldon T Brown; Jeffrey Samet; Lewis Kazis; Kendall Bryant; Amy C Justice
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-06-28

5.  Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.

Authors:  Susanna Naggie; Curtis Cooper; Michael Saag; Kimberly Workowski; Peter Ruane; William J Towner; Kristen Marks; Anne Luetkemeyer; Rachel P Baden; Paul E Sax; Edward Gane; Jorge Santana-Bagur; Luisa M Stamm; Jenny C Yang; Polina German; Hadas Dvory-Sobol; Liyun Ni; Phillip S Pang; John G McHutchison; Catherine A M Stedman; Javier O Morales-Ramirez; Norbert Bräu; Dushyantha Jayaweera; Amy E Colson; Pablo Tebas; David K Wong; Douglas Dieterich; Mark Sulkowski
Journal:  N Engl J Med       Date:  2015-07-21       Impact factor: 91.245

6.  Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women.

Authors:  Vincent Lo Re; Kenneth Lynn; Emily R Stumm; Jin Long; Melissa S Nezamzadeh; Joshua F Baker; Andrew N Hoofnagle; Angela J Kapalko; Karam Mounzer; Babette S Zemel; Pablo Tebas; Jay R Kostman; Mary B Leonard
Journal:  J Infect Dis       Date:  2015-03-09       Impact factor: 5.226

7.  Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis.

Authors:  Adriaan J van der Meer; Bart J Veldt; Jordan J Feld; Heiner Wedemeyer; Jean-François Dufour; Frank Lammert; Andres Duarte-Rojo; E Jenny Heathcote; Michael P Manns; Lorenz Kuske; Stefan Zeuzem; W Peter Hofmann; Robert J de Knegt; Bettina E Hansen; Harry L A Janssen
Journal:  JAMA       Date:  2012-12-26       Impact factor: 56.272

8.  Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.

Authors:  Z M Younossi; B R Bacon; D T Dieterich; S L Flamm; K Kowdley; S Milligan; N Tsai; A Nezam
Journal:  J Viral Hepat       Date:  2016-02-03       Impact factor: 3.728

9.  Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots.

Authors:  K-L Milner; A B Jenkins; M Trenell; J Tid-Ang; D Samocha-Bonet; M Weltman; A Xu; J George; D J Chisholm
Journal:  J Viral Hepat       Date:  2013-08-12       Impact factor: 3.728

10.  Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial.

Authors:  Jürgen K Rockstroh; Mark Nelson; Christine Katlama; Jay Lalezari; Josep Mallolas; Mark Bloch; Gail V Matthews; Michael S Saag; Philippe J Zamor; Chloe Orkin; Jacqueline Gress; Stephanie Klopfer; Melissa Shaughnessy; Janice Wahl; Bach-Yen T Nguyen; Eliav Barr; Heather L Platt; Michael N Robertson; Mark Sulkowski
Journal:  Lancet HIV       Date:  2015-07-09       Impact factor: 16.070
View more
  1 in total

1.  Hepatitis C virus cure does not impact kidney function decline in HIV co-infected patients.

Authors:  Carmine Rossi; Sahar Saeed; Joseph Cox; Marie-Louise Vachon; Valérie Martel-Laferrière; Sharon L Walmsley; Curtis Cooper; M John Gill; Mark Hull; Erica E M Moodie; Marina B Klein
Journal:  AIDS       Date:  2018-03-27       Impact factor: 4.177
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.